Back to Search
Start Over
Merck discontinues vibostolimab-Keytruda combination arm of Phase 3 trial
- Source :
- The Fly. May 13, 2024
- Publication Year :
- 2024
-
Abstract
- Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.793608745